A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of DWC202313 and DWC202314 in Healthy Adult Volunteers

NCT06119958 Phase 1 UNKNOWN

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Details

Lead sponsor	Daewoong Pharmaceutical Co. LTD.
Phase	Phase 1
Status	UNKNOWN
Enrolment	32
Start date	2023-10-27
Completion	2023-12

Conditions

• Drug Drug Interaction

Interventions

• DWC202313
• DWC202314

Primary outcomes

• Cmax,ss of DWC202313 and DWC202314 — Up to 14 days
• AUCt,ss of DWC202313 and DWC202314 — Up to 14 days

Countries

South Korea